Roflumilast
|
|
Roflumilast ??
- ???
- 158°C
- ?? ?
- 430.6±45.0 °C(Predicted)
- ??
- 1.471±0.06 g/cm3(Predicted)
- ?? ??
- -20°C
- ???
- DMSO: ???20mg/mL, ??
- ?? ?? (pKa)
- 9.89±0.70(Predicted)
- ??? ??
- ??
- ??
- ???? ????
- Merck
- 14,8249
- ???
- ??? ?? ?????? 1? ?? ??????. DMSO ??? -20°C?? ?? 3?? ?? ??? ? ????.
- InChI
- InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)
- InChIKey
- MNDBXUUTURYVHR-UHFFFAOYSA-N
- SMILES
- C(NC1C(Cl)=CN=CC=1Cl)(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1
- CAS ??????
- 162401-32-3(CAS DataBase Reference)
??
- ?? ? ?? ??
- ?? ? ???? ?? (GHS)
| ??? ?? | Xi | ||
|---|---|---|---|
| ?? ???? ?? | 36/37/38 | ||
| ????? | 26 | ||
| WGK ?? | 3 | ||
| RTECS ?? | CV3325600 | ||
| HS ?? | 2933.39.4100 | ||
| ???? ??? | 11 - Combustible Solids | ||
| Hazard Classifications | Eye Irrit. 2 Skin Irrit. 2 STOT SE 3 |
Roflumilast C??? ??, ??, ??
??
Roflumilast is a selective, orally active PDE4 inhibitor thatwas approved in Germany in July 2010 as an add-on to bronchodilator treatment for maintenance therapy of severe chronic obstructive pulmonary disorder (COPD) associated with chronic bronchitis in adult patients with a history of frequent exacerbations .Roflumilast and its primary metabolite roflumilast N-oxide are potent and competitive inhibitors of PDE4 and are equipotent against PDE4A, B, andD but inactive against PDE4C and the other ten members of the PDE family (PDEs 1–3, 5–11). Despite its inhibition of PDE4D (IC50=0.80 nM, N-oxide IC50=2.0 nM), roflumilast shows the lowest incidence of nausea (3–5%) among the PDE4 inhibitors investigated in clinical trials.Anti-inflammatory effects of roflumilast have been demonstrated in preclinical cellular and animal models. Roflumilast is synthesized in four steps from 3-(cyclopropylmethoxy)-4-hydroxybenzaldehyde. The difluoromethyl ether is introduced by alkylation of the free phenolic group with chlorodifluoromethane and base. The aldehyde moiety is oxidized to the benzoic acid, which is then converted to an acid chloride and coupled with 3,5-dichloro-4-aminopyridine. Roflumilast is rapidly absorbed and metabolized to its active metabolite, roflumilast N-oxide. Metabolism is mediated by CYP3A4 and CYP1A2.
??? ??
Crystallin Solid??
Roflumilast (Daxas) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM.??
ChEBI: A benzamide obtained by formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine. Used for treatment of bronchial asthma and chronic obstructive pulmonary diseaseMechanism of action
Roflumilast is the more potent of the two drugs, and along with its active metabolite, roflumilast-N-oxide, it is nonselective in its inhibitory action on PDE4B and PDE4D. The PDE4B appears to be the most closely linked to anti-inflammatory effects, whereas the PDE4D receptor subtype is thought to be linked to nausea, possibly through a central effect. Roflumilast exhibits 80% oral bioavailability and has an elimination half-life of 10 hours, whereas the N-oxide has an elimination half-life of 20 hours and has shown no drug interactions. Clinical trials in patients with asthma or COPD are quite promising.Pharmacokinetics
Roflumilast is well absorbed on oral administration and has a half-life of 10 hours. Roflumilast is metabolized in the liver to its N-oxide derivative, which also is a PDE4 inhibitor, and it has a plasma half-life of 20 hours.Clinical Use
Roflumilast is currently undergoing clinical trials in Europe for use in the treatment of both asthma and COPD.???
Common side effects of Roflumilast include: diarrhoea, nausea, dizziness, headache, back pain, muscle cramps, loss of appetite and weight loss. Severe can lead to persistent diarrhoea, acute pancreatitis, significant weight loss and psychiatric symptoms (such as anxiety, depression, insomnia and suicidal tendencies). In addition, the incidence of prostate, lung and colorectal cancer is significantly higher.Roflumilast ?? ?? ? ???
???
?? ??
Roflumilast ?? ??
???( 525)?? ??
| ??? | ?? | ??? | ?? | ?? ? | ?? |
|---|---|---|---|---|---|
| Hebei Chuanghai Biotechnology Co., Ltd | +8615350571055 |
Sibel@chuanghaibio.com | China | 8738 | 58 |
| Shaanxi Didu New Materials Co. Ltd | +86-86-17392712697 +8617792793228 |
1069@dideu.com | China | 8662 | 58 |
| Henan Bao Enluo International TradeCo.,LTD | +86-17331933971 |
deasea125996@gmail.com | China | 2472 | 58 |
| Anhui Ruihan Technology Co., Ltd | +8617756083858 |
daisy@anhuiruihan.com | China | 973 | 58 |
| BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 |
sales@sjar-tech.com | China | 529 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 |
info@tianfuchem.com | China | 21586 | 55 |
| Nanjing ChemLin Chemical Industry Co., Ltd. | 025-83697070 |
product@chemlin.com.cn | CHINA | 3009 | 60 |
| Shanghai Yingrui Biopharma Co., Ltd. | +86-21-33585366 - 03@ |
sales03@shyrchem.com | CHINA | 738 | 60 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 33024 | 60 |
| career henan chemical co | +86-0371-86658258 +8613203830695 |
sales@coreychem.com | China | 29815 | 58 |
Roflumilast ?? ??:
P-????????? ?????? ?????? 2-???-5-???????? ????????????
Montelukast
Montelukast sodium
Chlorantraniliprole
Fleroxacin
Ezetimibe
4-(DIFLUOROMETHOXY)-3-(CYCLOPROPYLMETHOXY)-BENZALDEHYDE
3-Cyclopropylmethoxy-4-difluoromethoxy-benzoic acid
benzaMide, N-(3,5-dichloro-4-pyridinyl)-4-(difluoroMethoxy)-3-hydroxy-
4-Amino-3,5-dichloropyridine
4-(Cyclopropylmethoxy)-3-(difluoromethoxy) Roflumilast
RofluMilast related substance
Roflumilast
RofluMilast N-Oxide




